Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
复制标题
抗肌肉生长抑制素抗体增加老年小鼠的肌肉质量和力量并改善胰岛素敏感性
DOI：
10.1073/pnas.1525795113
复制
发表时间：
2016-02-23
影响因子：
11.1
通讯作者：
Shulman, Gerald I.
中科院分区：
文献类型：
--
作者：
Camporez, Joao-Paulo G.;Petersen, Max C.;Shulman, Gerald I.
骨骼肌减少症或骨骼肌萎缩是许多生理和病理生理过程（包括正常衰老）的衰弱性共病。目前还没有批准的治疗肌肉减少症的方法，但抗肥厚肌生长抑制素是一个潜在的治疗靶点。在这里，我们发现用抗肌肉生长抑制素抗体（ATA 842）治疗年轻和年老小鼠4周后，两组的肌肉质量和肌肉力量都增加了。此外，ATA 842治疗还增加了胰岛素刺激的老年小鼠全身葡萄糖代谢，这可能归因于胰岛素刺激的骨骼肌葡萄糖摄取增加，通过高胰岛素-血糖钳测量。综上所述，这些研究为肌生长抑制素的药理学抑制作为治疗与年龄相关的肌肉减少症和代谢性疾病的潜在方法提供了支持。
Sarcopenia, or skeletal muscle atrophy, is a debilitating comorbidity of many physiological and pathophysiological processes, including normal aging. There are no approved therapies for sarcopenia, but the antihypertrophic myokine myostatin is a potential therapeutic target. Here, we show that treatment of young and old mice with an anti-myostatin antibody (ATA 842) for 4 wk increased muscle mass and muscle strength in both groups. Furthermore, ATA 842 treatment also increased insulin-stimulated whole body glucose metabolism in old mice, which could be attributed to increased insulin-stimulated skeletal muscle glucose uptake as measured by a hyperinsulinemic-euglycemic clamp. Taken together, these studies provide support for pharmacological inhibition of myostatin as a potential therapeutic approach for age-related sarcopenia and metabolic disease.